Anti-CD19/BCMA CAR-T cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs”In the company’s words, NCT03879382 on ClinicalTrials.gov
- Tested for
- POMES Syndrome, Relapsed and Refractory POMES Syndrome
- Main trialPhase 1
- “The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.”In the company’s words, NCT03879382 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 30 Aug 2020 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026